Cargando…

Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report

BACKGROUND: Primary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy. CASE PRESENTATION: A 75 year old woman with laparoscopically and histologically confirmed unresectable OC was...

Descripción completa

Detalles Bibliográficos
Autores principales: Tempfer, Clemens B., Hartmann, Franziska, Hilal, Ziad, Rezniczek, Günther A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216537/
https://www.ncbi.nlm.nih.gov/pubmed/28061769
http://dx.doi.org/10.1186/s12885-016-3004-8
_version_ 1782491931234795520
author Tempfer, Clemens B.
Hartmann, Franziska
Hilal, Ziad
Rezniczek, Günther A.
author_facet Tempfer, Clemens B.
Hartmann, Franziska
Hilal, Ziad
Rezniczek, Günther A.
author_sort Tempfer, Clemens B.
collection PubMed
description BACKGROUND: Primary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy. CASE PRESENTATION: A 75 year old woman with laparoscopically and histologically confirmed unresectable OC was treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m(2) and doxorubicin 1.5 mg/m(2) over 2 years using laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC). Objective tumor response (tumor regression on histology, stable disease on repeated video-laparoscopy and peritoneal carcinomatosis index) was noted. No Common Terminology Criteria for Adverse Events (CTCAE) > grade 3 were observed. EORTC QLQ-C30 quality of life measurements were stable throughout the therapy. CONCLUSIONS: Repeated intraperitoneal chemotherapy with cisplatin and doxorubicin applied as PIPAC may be an effective maintenance treatment in women with primary advanced, unresectable OC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-3004-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5216537
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52165372017-01-09 Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report Tempfer, Clemens B. Hartmann, Franziska Hilal, Ziad Rezniczek, Günther A. BMC Cancer Case Report BACKGROUND: Primary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy. CASE PRESENTATION: A 75 year old woman with laparoscopically and histologically confirmed unresectable OC was treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m(2) and doxorubicin 1.5 mg/m(2) over 2 years using laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC). Objective tumor response (tumor regression on histology, stable disease on repeated video-laparoscopy and peritoneal carcinomatosis index) was noted. No Common Terminology Criteria for Adverse Events (CTCAE) > grade 3 were observed. EORTC QLQ-C30 quality of life measurements were stable throughout the therapy. CONCLUSIONS: Repeated intraperitoneal chemotherapy with cisplatin and doxorubicin applied as PIPAC may be an effective maintenance treatment in women with primary advanced, unresectable OC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-3004-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-06 /pmc/articles/PMC5216537/ /pubmed/28061769 http://dx.doi.org/10.1186/s12885-016-3004-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Tempfer, Clemens B.
Hartmann, Franziska
Hilal, Ziad
Rezniczek, Günther A.
Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
title Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
title_full Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
title_fullStr Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
title_full_unstemmed Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
title_short Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
title_sort intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216537/
https://www.ncbi.nlm.nih.gov/pubmed/28061769
http://dx.doi.org/10.1186/s12885-016-3004-8
work_keys_str_mv AT tempferclemensb intraperitonealcisplatinanddoxorubicinasmaintenancechemotherapyforunresectableovariancanceracasereport
AT hartmannfranziska intraperitonealcisplatinanddoxorubicinasmaintenancechemotherapyforunresectableovariancanceracasereport
AT hilalziad intraperitonealcisplatinanddoxorubicinasmaintenancechemotherapyforunresectableovariancanceracasereport
AT rezniczekgunthera intraperitonealcisplatinanddoxorubicinasmaintenancechemotherapyforunresectableovariancanceracasereport